Royal Bank of Canada’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $0 | Sell |
45
-35
| -44% | -$42 | ﹤0.01% | 7093 |
|
|
2025
Q4 | $0 | Sell |
80
-5,637
| -99% | -$8.22K | ﹤0.01% | 7149 |
|
|
2025
Q3 | $9K | Buy |
5,717
+53
| +0.9% | +$86 | ﹤0.01% | 6509 |
|
|
2025
Q2 | $8K | Buy |
5,664
+4,384
| +343% | +$6.56K | ﹤0.01% | 6524 |
|
|
2025
Q1 | $2K | Sell |
1,280
-4,813
| -79% | -$6.11K | ﹤0.01% | 6547 |
|
|
2024
Q4 | $8K | Sell |
6,093
-2,149
| -26% | -$3.33K | ﹤0.01% | 6394 |
|
|
2024
Q3 | $15K | Buy |
8,242
+48
| +0.6% | +$190 | ﹤0.01% | 6195 |
|
|
2024
Q2 | $61K | Buy |
8,194
+2,706
| +49% | +$22.3K | ﹤0.01% | 5550 |
|
|
2024
Q1 | $43K | Sell |
5,488
-8,046
| -59% | -$51.7K | ﹤0.01% | 5600 |
|
|
2023
Q4 | $69K | Buy |
13,534
+5,086
| +60% | +$26.2K | ﹤0.01% | 5830 |
|
|
2023
Q3 | $49K | Buy |
8,448
+1,714
| +25% | +$11.4K | ﹤0.01% | 5790 |
|
|
2023
Q2 | $49K | Buy |
6,734
+1,871
| +38% | +$15.9K | ﹤0.01% | 5787 |
|
|
2023
Q1 | $46K | Buy |
4,863
+2,200
| +83% | +$23.2K | ﹤0.01% | 5661 |
|
|
2022
Q4 | $29K | Buy |
2,663
+2,606
| +4,572% | +$26.4K | ﹤0.01% | 6145 |
|
|
2022
Q3 | $0 | Buy |
+57
| New | +$354 | ﹤0.01% | 7425 |
|
|
2022
Q2 | – | Sell |
-406
| Closed | -$2K | – | 7351 |
|
|
2022
Q1 | $2K | Buy |
406
+400
| +6,667% | +$2.11K | ﹤0.01% | 7456 |
|
|
2021
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 7637 |
|
|
2021
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 7614 |
|
|
2021
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 7462 |
|
|
2021
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 7403 |
|
|
2020
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 7053 |
|
|
2020
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 6599 |
|
|
2020
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 6608 |
|
|
2020
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 6648 |
|
|
2019
Q4 | $0 | Buy |
+6
| New | +$41 | ﹤0.01% | 6805 |
|
|
2018
Q2 | – | Sell |
-82
| Closed | -$1K | – | 6499 |
|
|
2018
Q1 | $1K | Sell |
82
-1
| -1% | -$17 | ﹤0.01% | 6182 |
|
|
2017
Q4 | $2K | Hold |
83
| – | – | ﹤0.01% | 6254 |
|
|
2017
Q3 | $1K | Sell |
83
-65
| -44% | -$1.43K | ﹤0.01% | 6608 |
|
|
2017
Q2 | $5K | Hold |
148
| – | – | ﹤0.01% | 6028 |
|
|
2017
Q1 | $7K | Hold |
148
| – | – | ﹤0.01% | 6095 |
|
|
2016
Q4 | $4K | Sell |
148
-67
| -31% | -$2.1K | ﹤0.01% | 6342 |
|
|
2016
Q3 | $8K | Sell |
215
-33
| -13% | -$1.69K | ﹤0.01% | 5841 |
|
|
2016
Q2 | $14K | Buy |
248
+166
| +202% | +$9.27K | ﹤0.01% | 5625 |
|
|
2016
Q1 | $5K | Sell |
82
-751
| -90% | -$47.4K | ﹤0.01% | 5914 |
|
|
2015
Q4 | $81K | Buy |
833
+829
| +20,725% | +$55.1K | ﹤0.01% | 5053 |
|
|
2015
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6624 |
|
|
2015
Q2 | $0 | Buy |
+4
| New | +$341 | ﹤0.01% | 6568 |
|
Other funds holding ATNM
VCM
GS
VFT
Royal Bank of Canada's ATNM Position: Q1 2026 in Review
Royal Bank of Canada reduced its Actinium Pharmaceuticals (ATNM) stake by 44% in Q1 2026, selling an estimated $42 and leaving 45 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7093.
Royal Bank of Canada first reported a position in ATNM in Q2 2015 and has held it in 37 quarters since. The position peaked at $81K in Q4 2015. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Royal Bank of Canada held 45 shares of Actinium Pharmaceuticals worth $0 as of Q1 2026.
- Royal Bank of Canada sold 35 Actinium Pharmaceuticals shares in Q1 2026, an estimated $42.
- Actinium Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7093 holding.
- Royal Bank of Canada first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
- Royal Bank of Canada's Actinium Pharmaceuticals position peaked at $81K in Q4 2015.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.